Seegene Launches STARlet-AIOS All-in-One System that Fulfills Critical Need for Fully Automated, High-Throughput Real-Time PCR Testing

By LabMedica International staff writers
Posted on 03 Nov 2021

Seegene, Inc. (Seoul, Korea) has launched its fully automated STARlet-AIOS: All-in-One System (AIOS) that addresses the needs of small, mid-sized, and large hospitals and COVID-19 laboratories.

First unveiled at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo in Atlanta, the modular system supports a "hands-free" PCR workflow, automating everything from nucleic acid extraction to the interpretation of results. This can help sites boost their testing capacity while lessening the burden on laboratory and hospital staff. The modular design of STARlet-AIOS: All-in-One System unites two standalone instruments - the STARlet IVD and the CFX96 Dx real-time PCR System - with a custom-built robotic arm. This unique engineering allows customers to either purchase the full AIOS system or integrate existing Seegene instruments already in use. With its compact and intuitive design, the AIOS is accessible to small-to-medium sized hospitals and clinics, along with larger organizations.


Image: STARlet-AIOS (Photo courtesy of Seegene, Inc.)

Seegene's current portfolio with an extensive test menu including GI, HPV, STI, respiratory assays as well as a suite of SARS-CoV-2 assays detecting a wide range of variants (namely, Alpha, Beta, Gamma, Delta, Epsilon, kappa, Lambda, Mu, etc.) can all be processed using the AIOS. The system will also be compatible with newly developed assays and Seegene's MOBILE STATION, an innovative laboratory-on-wheels initiative that delivers mass testing capacity to communities that would otherwise lack the necessary infrastructure.

"Seegene has played a critical role in the global response to the COVID-19 pandemic, in large part because of our forward-looking strategy. We moved fast from day one, rapidly developing a reliable assay for the novel coronavirus and then pivoting to multiplexed tests that can detect emerging SARS-CoV-2 variants," said Dr. Jong-Yoon Chun, Seegene Founder and CEO. "As we look ahead, the most pressing diagnostic need will be for cost-effective and high throughput automated systems that can remove any remaining testing bottlenecks. Our all-in-one system specifically addresses that need for hospitals and laboratories of all sizes."

Related Links:
Seegene, Inc.


Latest Molecular Diagnostics News